Today's Peptide News — September 14, 2026

A January 2026 review in Frontiers in Drug Delivery on the pharmacokinetic boundaries of oral peptide delivery spotlights a new generation of macrocyclic peptides engineered to survive the gut and reach systemic circulation. Its flagship example is MK-0616, an oral macrocyclic peptide PCSK9 inhibitor from Merck that produced LDL cholesterol reductions of up to 60.9% in Phase 2b trials, alongside Luna-18, an oral macrocyclic candidate aimed at metabolic indications.

The result matters because injectable PCSK9-targeting antibodies already lower LDL powerfully, but their needle-based delivery limits uptake for a chronic, largely asymptomatic condition. An oral peptide that reaches comparable efficacy would fold a best-in-class cholesterol mechanism into a daily pill, and it demonstrates that the oral-bioavailability wall long associated with peptides is starting to crack for carefully constrained macrocycles.

A short PeptideWiki post could frame MK-0616 as the proof-of-concept for oral macrocyclic peptides: explain how cyclization and backbone modification shield the molecule from gut proteases and improve membrane permeability, then use the 61% LDL figure as the hook for why cardiologists are watching this class.

An August 2026 review in Cell Chemical Biology surveys nature-inspired macrocyclic peptides and the molecular engineering strategies used to turn them into drugs. The authors organize representative macrocycles by the three properties that decide whether a peptide can become an oral therapeutic — membrane permeability, proteolytic stability, and oral bioavailability — and show how ring-closing scaffolds inspired by natural products overcome the limitations that leave linear peptides trapped as injectables.

This is a useful anchor piece because it reframes the peptide field's central problem in design terms rather than delivery-device terms. Instead of asking how to protect a fragile peptide, the review asks how to build a peptide that does not need protecting, drawing on cyclic templates that evolution already optimized for stability and target engagement.

A PeptideWiki angle: a primer on why macrocyclization is the dominant strategy for next-generation peptide drugs, pairing the review's three-property framework with concrete clinical examples like MK-0616 so readers see the theory and the pipeline together.

PeptiVerse, posted to bioRxiv, is a machine-learning platform that predicts the developability properties of therapeutic peptides directly from either amino acid sequences or the SMILES strings of chemically modified peptides. The authors report state-of-the-art performance across a range of property-prediction tasks and release both a web interface and an open-source implementation, positioning the tool for rapid, scalable screening early in peptide discovery.

The finding matters because chemical modification — cyclization, non-natural residues, lipidation — is exactly what makes modern peptides drug-like, yet most predictive models only handle plain sequences and cannot reason about those modifications. By accepting modified-peptide SMILES, PeptiVerse lets researchers triage candidate designs computationally before committing to synthesis, compressing one of the slowest loops in peptide development.

For PeptideWiki, this is a strong explainer on how AI is reshaping peptide design: a short post could walk through what "developability" means for a peptide, why modeling chemical modifications is the hard part, and how open tools like PeptiVerse lower the barrier for smaller labs to design better candidates.

Eli Lilly's retatrutide, a triple agonist that simultaneously targets the GLP-1, GIP, and glucagon receptors, has now finished all four core Phase 3 studies in its TRIUMPH program, with TRIUMPH-2 in obesity plus diabetes and TRIUMPH-3 in obesity plus cardiovascular disease both confirmed complete. TRIUMPH-1 previously delivered average weight loss of 28.3% at the 12 mg dose over 80 weeks, with a blinded extension reaching 30.3% at 104 weeks. TRIUMPH-2 showed up to 20.8% weight loss with meaningful HbA1c reductions, and TRIUMPH-3 reached up to 22.6% weight loss with improvements in triglycerides, blood pressure, and inflammatory markers.

This matters because retatrutide's triple-agonist mechanism is producing the largest weight-loss figures reported in Phase 3 obesity trials to date, extending the incretin story beyond the dual GLP-1/GIP agonism of tirzepatide. A regulatory filing is expected late in 2026, with approval unlikely before 2027 or 2028.

A PeptideWiki post could contrast the two-hormone and three-hormone incretin strategies, using retatrutide to explain what adding glucagon-receptor agonism does for energy expenditure and why that may push efficacy higher than dual agonists.

An FDA advisory committee reviewed seven peptides on July 23 and 24, 2026, and recommended six of them for inclusion on the 503A compounding list, while emideltide (DSIP) was not advanced. The votes are the latest step in a regulatory tightening that has been reshaping how compounding pharmacies can handle peptides, following the earlier removal of a dozen peptides — including BPC-157, LL-37, Epitalon, GHK-Cu, MOTS-c, and TB-500 — from the agency's category 2 list after nominations were withdrawn.

The development matters because it marks a clearer boundary between peptides that can be legally compounded and the large gray market of research peptides sold without formal approval. Companies are increasingly being pushed toward formal drug-development pathways that meet established safety, efficacy, and manufacturing standards rather than relying on compounding tolerance.

A PeptideWiki angle: a plain-language explainer of what the 503A list is, why a peptide's placement on or off it determines whether patients can legally access it through a compounding pharmacy, and what the July votes signal for the broader research-peptide market.

A large Swedish observational study of nearly 15,000 people with bipolar disorder found that semaglutide use was associated with a 21% lower risk of psychiatric hospitalization and a 17% lower risk of hospitalization for a bipolar relapse. Notably, the same protective signal did not appear for the other GLP-1 receptor agonists examined, liraglutide and dulaglutide, hinting at something specific to semaglutide's profile rather than a general incretin-class effect.

The researchers stress heavy caveats: this is observational data that cannot establish that semaglutide prevents psychiatric hospitalization or treats bipolar disorder, and confounding is hard to rule out. Still, the proposed mechanism is biologically interesting — GLP-1 signaling in the brain may dampen inflammation and cellular stress, processes increasingly linked to mood disorders.

For PeptideWiki, this fits a growing "GLP-1 beyond weight loss" theme. A short post could catalog the emerging neuropsychiatric signals for semaglutide, explain the brain GLP-1 receptor mechanism, and be careful to frame the evidence as hypothesis-generating rather than practice-changing.

A team led by Dr. Manel Esteller at the Josep Carreras Leukemia Research Institute published what it describes as the most comprehensive study ever performed on a supercentenarian, profiling Maria Branyas, who lived past 117, across her genome, proteome, epigenome, metabolome, transcriptome, and microbiome using minimally invasive blood, saliva, urine, and stool samples. The striking finding is a biological duality: signals of extreme aging and of healthy longevity present at the same time.

On the aging side, researchers found very short telomeres, a pro-inflammatory immune profile, and an aged population of B lymphocytes. On the protective side, they measured low overall inflammation, beneficial gut bacteria, favorable genetic variants, and multiple biological clocks placing her biological age more than 23 years below her chronological age. The picture suggests extreme longevity is not simply the absence of aging but the coexistence of aging with unusually strong biological buffering.

It matters because it reframes how researchers think about the oldest humans: rather than searching for people who don't age, the study points toward mechanisms that let the body tolerate aging's damage, a subtly different target for longevity science.

A survey of 1,102 U.S. men conducted by Morning Consult for the Physicians Committee for Responsible Medicine found that just 20% were aware research has linked dairy consumption to increased prostate cancer risk, and only 20% had received any information from a healthcare professional connecting nutrition to prostate cancer. After learning of the association, 66% said they would consider avoiding dairy, and 76% supported warning labels on dairy products.

The awareness gap is notable given the epidemiological signal behind it: in the cited research, men who consumed the most whole milk had a prostate cancer death risk as much as 50% higher than those who consumed the least. Prostate cancer is one of the most common cancers in men, making dietary risk factors a meaningful lever for prevention conversations.

The story matters as a public-health communication problem more than a new scientific finding — the link has been studied for years, but it has not reached patients, and the survey quantifies just how wide that gap remains.

A team at TU Wien, working with the University of Vienna, JKU Linz, and the University of Innsbruck, has developed a way to harness the quantum information carried by electrons in an electron microscope by coupling the electron beam to a quantum computer built from trapped ions. In a conventional instrument, electrons are essentially just counted to build an image, and the quantum information each electron carries goes unused; the new approach creates quantum entanglement between electrons and trapped ions to combine information across multiple electrons.

The payoff is the ability to extract clearer images while exposing a sample to far fewer electrons, which matters most for fragile specimens — biological materials and delicate structures that conventional electron microscopy can damage or destroy during imaging. The method could reveal faint details that would otherwise require a damaging electron dose.

The work has been accepted for publication in Physical Review Letters and is available as an arXiv preprint, and the quantum-computer electron microscope is now being built at TU Wien, marking an early, concrete application where a small quantum device delivers a measurable advantage over classical instrumentation.